Computer system validation software: six paperless validation tools read against Part 11

Every paper habit in a validation binder answers a rule. The wet-ink signature, the single-line correction and the stapled screenshot are how a paper record shows who did what, when, and on what evidence. Part 11 asks the same of an electronic record, so a paperless tool is worth buying only if each habit has a control behind it.

FDA's Computer Software Assurance guidance (final in September 2025, reissued February 3, 2026 for “Production and Quality Management System Software”) names two families of testing. Scripted testing is the paper protocol. Unscripted testing is “Dynamic testing in which the tester's actions are not prescribed by written instructions in a test case”, and covers scenario testing, error guessing and exploratory testing.

For high process risk features, manufacturers “may choose to consider more rigor such as the use of scripted testing or a hybrid approach”; for the rest they “may consider using unscripted testing methods”. A tool built only around pre-approved, step-by-step protocols forces scripted testing onto every feature, which is the paper habit moved online. Check that it can hold each record FDA describes.

FDA also says where the evidence should come from: “FDA recommends incorporating the use of digital records, such as system logs, audit trails, and other data generated and maintained by the software, as opposed to paper documentation, screenshots, or duplicating results already digitally retained by the software”. A tool that wants a screenshot for every step brings back the stapled printout, and FDA adds that the record “need not include more evidence than necessary”.

A paperless validation tool holds the evidence that every other system works. FDA's CSA guidance sorts software by intended use: software that maintains “a quality record” is used directly in the quality system, while “development tools that test or monitor software systems or that automate testing activities” support it. Both, it says, are used as part of production or the quality system and “must be validated” under ISO 13485 4.1.6, 7.5.6 or 7.6, which the QMSR incorporates by reference into Part 820.

Supporting software “often carries lower risk”, and FDA says its assurance may be established “by leveraging vendor evaluation and validation records, software installation, or software configuration”. Read FDA's own example closely, though: a load-testing tool gets that lighter treatment partly because it “is not the system of record of the testing result”. A paperless validation tool is exactly that system of record. Once your executed protocols live in it, CSA's Part 11 section applies: a record “necessary as evidence to document required validation” and kept in electronic form is generally a Part 11 record.

For a drug or GLP lab the duty reads differently but lands in the same place: § 11.10(a) asks for “Validation of systems to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records”, and Annex 11 opens with “The application should be validated”. FDA's 2003 guidance uses enforcement discretion on the Part 11 version of validation, but CSA says that discretion “expressly does not apply” to a device maker's ISO 13485 validation duty, and FDA enforces every predicate rule either way.

On the vendors' own pages we read, Kneat Gx, Veeva Validation Management and Valkit.ai describe validation documentation for customers; the table below shows the rest. Write the tool's intended use into a user requirement specification, list it in your validation master plan with the other systems, and size the testing per feature by risk. Decide in the plan where the tool's own validation record lives, and why.

Ten rows, read on each vendor's own pages. Filter them to the rows you care about most: signing a protocol, keeping the evidence, or open systems and EU Annex 11.

A stated row is a claim in general words, often a product-level Part 11 claim, with no page that describes the control. Ask for the document behind it and read it against these rows before a demo. ValGenesis is the case in point: every row it covers here is stated, and it publishes its Part 11 and Annex 11 assessments for VLMS as white papers, so those papers are the first thing to ask for.

Veeva Validation Management documents the most here: 8 of 10 rows are described on its own pages. Documentation is only half of the choice. If your software testing already lives in Jira or Tricentis tools, Tricentis Vera signs the test records where they are rather than copying results into a second system. If most of your validation load is equipment and process qualification across sites, the lifecycle suites that cover CQV as well as CSV are the closer fit.

Before any demo, write what you need into a URS: the signature meanings your procedures use, who may execute and who may approve, how deviations are raised, and what the exported package must contain.

Deviation capture, re-execution, unscripted records and trace updates decide how a validation tool feels to use, and none of them is in our register: we read no vendor's pages on them, so we give no status. Ask each vendor to run one short protocol through every step below, live, in the order given.

Keep the protocol you used: it becomes the first scenario test in your own validation of the tool. The IQ OQ PQ template gives the scripted form and the traceability matrix template the trace to check the tool's against.

Each card shows the six rows a validation record leans on: the signature, its link to the record, the trail, the exported copy, who may sign, and the vendor's validation documentation. A product not listed here is not a verdict on it.

1. 21 CFR Part 11, Electronic Records; Electronic Signatures, eCFRread 2026-10-22
2. Computer Software Assurance for Production and Quality Management System Software (guidance, February 3, 2026), FDAread 2026-10-22
3. Computer Software Assurance guidance, full text (PDF), FDAread 2026-10-22
4. Computer Software Assurance final guidance, notice of availability, 90 FR 45945 (2025), Federal Registerread 2026-10-22
5. Part 11, Electronic Records; Electronic Signatures: Scope and Application (guidance, 2003), FDAread 2026-10-22
6. Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers (2024), FDAread 2026-10-22
7. 21 CFR Part 820, Quality Management System Regulation, eCFRread 2026-10-22
8. 21 CFR Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies, eCFRread 2026-10-22
9. EudraLex Volume 4, Annex 11: Computerised Systems (2011), European Commissionread 2026-10-22
10. Stakeholders' consultation on EudraLex Volume 4: Chapter 4, Annex 11 and new Annex 22, European Commissionread 2026-10-22
11. GAMP 5 Guide, 2nd Edition (product page), ISPEread 2026-10-22